NICE reject Avastin for advanced breast cancer: The National Institute for Health and Clinical Excellence (NICE) has decided a drug for women with breast cancer that has spread should not be available on the NHS.
The decision comes despite evidence that Avastin can stall progression of the disease for three months.
NICE has issued draft guidance on Avastin, also known as bevacizumab, which says that the drug which costs more than £3,500 a month for ... Healthcare Today
The decision comes despite evidence that Avastin can stall progression of the disease for three months.
NICE has issued draft guidance on Avastin, also known as bevacizumab, which says that the drug which costs more than £3,500 a month for ... Healthcare Today
No comments:
Post a Comment